BOEHRINGER INGELHEIM Overview
Upcoming Projects (BOEHRINGER INGELHEIM)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BOEHRINGER INGELHEIM)
-
A Third Look: Delving into the recent topline data from the FIBRONEER-IPF clinical trial of nerandomilast in patients with IPF
Ticker: BOEHRINGER INGELHEIM
Executed On: Oct 10, 2024 at 03:15 PM EDT -
A Second Look: Delving into the recent topline data from the FIBRONEER-IPF clinical trial of nerandomilast in patients with IPF
Ticker: BOEHRINGER INGELHEIM
Executed On: Oct 04, 2024 at 11:00 AM EDT -
Delving into the recent topline data from the FIBRONEER-IPF clinical trial of nerandomilast in patients with IPF
Ticker: BOEHRINGER INGELHEIM
Executed On: Oct 02, 2024 at 04:00 PM EDT -
A Third Opinion: An updated look at the phase 2 data from Boehringer Ingelheim's and Zealand Pharmaceuticals Survodutide for the treatment of MASH.
Tickers: BOEHRINGER INGELHEIM, ZEAL
Executed On: Jul 25, 2024 at 01:00 PM EDT -
A Second Opinion: An updated look at the phase 2 data from Boehringer Ingelheim's and Zealand Pharmaceuticals Survodutide for the treatment of MASH.
Tickers: BOEHRINGER INGELHEIM, ZEAL
Executed On: Jul 24, 2024 at 03:00 PM EDT -
An updated look at the phase 2 data from Boehringer Ingelheim's and Zealand Pharmaceuticals Survodutide for the treatment of MASH.
Tickers: BOEHRINGER INGELHEIM, ZEAL
Executed On: Jun 25, 2024 at 04:00 PM EDT -
A Third Look: Discussing the potential of Boehringer Ingelheim's Survodutide for the treatment of MASH.
Ticker: BOEHRINGER INGELHEIM
Executed On: Apr 09, 2024 at 05:30 PM EDT -
A Second Look: Discussing the potential of Boehringer Ingelheim's Survodutide for the treatment of MASH.
Ticker: BOEHRINGER INGELHEIM
Executed On: Apr 03, 2024 at 04:00 PM EDT -
Discussing the potential of Boehringer Ingelheim's Survodutide for the treatment of MASH.
Ticker: BOEHRINGER INGELHEIM
Executed On: Mar 18, 2024 at 12:30 PM EDT -
A Second Look: Discussing the potential of BI 690517 in combination with Jardiance for reducing urinary albumin-to-creatinine ratio (UACR) in patients with CKD
Tickers: BOEHRINGER INGELHEIM, LLY
Executed On: Dec 21, 2023 at 04:00 PM EST -
Discussing the potential of BI 690517 in combination with Jardiance for reducing urinary albumin-to-creatinine ratio (UACR) in patients with CKD
Tickers: BOEHRINGER INGELHEIM, LLY
Executed On: Dec 21, 2023 at 08:30 AM EST -
A Second Look: Investigating the recent phase 3 DINAMO clinical trial data on Jardiance (empagliflozin) and Tradjenta (linagliptin) in pediatric patients with type-2 diabetes.
Tickers: LLY, Boehringer Ingelheim
Executed On: Sep 29, 2023 at 04:00 PM EDT -
A Second Look: Discussing the current standard of care for ILD and speaking on the potential use of OFEV (nintedanib) in the pediatric population.
Ticker: BOEHRINGER INGELHEIM
Executed On: Sep 27, 2023 at 05:20 PM EDT -
Discussing the current standard of care of ILD and speaking on the potential use of OFEV (nintedanib) in the pediatric population.
Ticker: BOEHRINGER INGELHEIM
Executed On: Sep 27, 2023 at 12:00 PM EDT -
Investigating the recent phase 3 DINAMO clinical trial data on Jardiance (empagliflozin) and Tradjenta (linagliptin) in pediatric patients with type-2 diabetes.
Tickers: LLY, Boehringer Ingelheim
Executed On: Aug 23, 2023 at 01:00 PM EDT -
A Third View: Looking into the phase 2 data on Zealand Pharma and Boehringer Ingelheim's Survodutide(BI 456906) for treating type 2 diabetes and obesity.
Tickers: ZEAL, Boehringer Ingelheim
Executed On: Aug 08, 2023 at 04:15 PM EDT -
A Second View: Looking into the phase 2 data on Zealand Pharma and Boehringer Ingelheim's Survodutide(BI 456906) for treating type 2 diabetes and obesity.
Tickers: ZEAL, Boehringer Ingelheim
Executed On: Aug 04, 2023 at 05:00 PM EDT -
Looking into the phase 2 data on Zealand Pharma and Boehringer Ingelheim's Survodutide(BI 456906) for treating type 2 diabetes and obesity.
Tickers: ZEAL, Boehringer Ingelheim
Executed On: Aug 03, 2023 at 11:00 AM EDT -
Discussing the standard of care and the potential of Boehringer Ingelheim's BI 456906, a novel glucagon/GLP-1 receptor dual agonist, once-weekly injectable to treat obesity.
Tickers: ZEAL, Boehringer Ingelheim
Executed On: May 17, 2023 at 05:30 PM EDT -
Gaining insight into the current treatment landscape including the use of Spevigo (spesolimab-sbzo) by Boehringer Ingelheim for the treatment of generalized pustular psoriasis.
Ticker: BOEHRINGER INGELHEIM
Executed On: Nov 02, 2022 at 12:00 PM EDT -
A second discussion of the clinical landscape of IPF, with a focus on the use of OFEV and its potential expansion into the pediatric population.
Ticker: BOEHRINGER INGELHEIM
Executed On: Oct 20, 2022 at 09:00 AM EDT -
Discussing the clinical landscape of IPF, with a focus on the use of OFEV and its potential expansion into the pediatric population.
Ticker: BOEHRINGER INGELHEIM
Executed On: Oct 17, 2022 at 03:00 PM EDT -
A second look at the prescribing habits of Jardiance to reduce the risk of cardiovascular death and hospitalization due to heart failure
Ticker: BOEHRINGER INGELHEIM
Executed On: Aug 22, 2022 at 02:45 PM EDT -
A third look at the prescribing habits of Jardiance to reduce the risk of cardiovascular death and hospitalization due to heart failure
Ticker: BOEHRINGER INGELHEIM
Executed On: Aug 22, 2022 at 02:00 PM EDT -
A look at the prescribing habits of Jardiance to reduce the risk of cardiovascular death and hospitalization due to heart failure
Tickers: BOEHRINGER INGELHEIM, NVS
Executed On: Aug 18, 2022 at 01:00 PM EDT
Upcoming & Overdue Catalysts (BOEHRINGER INGELHEIM)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (BOEHRINGER INGELHEIM)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
